Galmed Pharmaceuticals (GLMD) Capital Expenditures (2013 - 2023)

Galmed Pharmaceuticals' Capital Expenditures history runs 11 years deep, the most recent figure standing at -$4000.0 for Q1 2023.

• In Q1 2023, Capital Expenditures fell 300.0% year-over-year to -$4000.0; the TTM figure through Mar 2023 stood at $1000.0 (down 90.91% YoY), while the FY2022 annual figure was $4000.0, down 63.64% from the prior year.
• Capital Expenditures was -$4000.0 for Q1 2023 at Galmed Pharmaceuticals, down from $7000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $77000.0 in Q4 2020 to a low of -$28000.0 in Q3 2020.
• Historically, Capital Expenditures has averaged $3692.3 across 5 years, with a median of -$2000.0 in 2021.
• Biggest YoY gain for Capital Expenditures was 2666.67% in 2020; the steepest drop was 460.0% in 2020.
• A 5-year view of Capital Expenditures shows it stood at -$3000.0 in 2019, then surged by 2666.67% to $77000.0 in 2020, then tumbled by 72.73% to $21000.0 in 2021, then tumbled by 66.67% to $7000.0 in 2022, then tumbled by 157.14% to -$4000.0 in 2023.
• The last three Capital Expenditures figures came in at -$4000.0 (Q1 2023), $7000.0 (Q4 2022), and -$2000.0 (Q2 2022), per Business Quant data.